STARHEALTH - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Fundamental Rating: 3.3

Here’s a full-spectrum view of Star Health and Allied Insurance (STARHEALTH) — one of India’s top standalone health insurers, balancing sector tailwinds with uneven profitability 📊🩺

📘 Core Financial Assessment

Profit Profile

PAT jumped to ₹263 Cr. this quarter from ₹0.51 Cr. previously, but flagged by a QoQ profit variation of –17.7%.

EPS stands at ₹10 — decent, but not strong relative to market price.

ROE: 9.57%, ROCE: 11.9% — moderate, signaling room to tighten operational returns.

Capital & Debt Structure

Debt-to-Equity not disclosed — insurers typically run low debt, relying on float and reserves.

Dividend Yield: 0.00% — standard for growth-stage financial firms reinvesting capital.

💰 Valuation Snapshot

Indicator Value Interpretation

P/E Ratio 43.4 Above industry average (39.0) — premium pricing

P/B Ratio NA Lack of disclosure may suggest recent restructuring or asset reinvestment

PEG Ratio 1.15 Acceptable — valuation roughly matches growth

Intrinsic Value ~₹390–₹420 Slightly overvalued at current ₹436

While not alarmingly pricey, investors appear to be pricing in future margin expansion and premium retention.

🧬 Business Model & Strategic Advantage

Core focus on retail health insurance, with broad distribution across hospitals, agents, and digital platforms.

Competitive moat built around specialization in health vs. diversified insurers.

Strong regulatory landscape and rising health awareness serve as long-term tailwinds.

📈 Institutional sentiment is mixed

FII Holdings dropped –4.8% — possibly profit-booking or valuation concerns

DII Holdings up +5.64% — indicating domestic conviction in medium-term story

📉 Technical View & Entry Opportunity

RSI: 51.2 — neutral territory, with scope for breakout or cooling.

MACD: +1.41 — mild bullish signal emerging.

Price hovering between DMA 50 (₹431) and DMA 200 (₹447) — suggests range-bound movement.

🎯 Recommended Entry Zone

Accumulate near ₹400–₹420

Deep value zone: ₹370–₹390, particularly during sector-wide dips or FII reversal

⏳ Long-Term Holding Guidance

✅ India’s underpenetrated health insurance market, rising demand, and specialist advantage

⚠️ Inconsistent quarterly profitability, modest ROE/ROCE, valuation still elevated

🟡 Suitable for 5+ year horizon, ideally in thematic portfolios aligned with health finance and insurance digitization

I can run a head-to-head against Niva Bupa, ICICI Lombard, or HDFC Ergo — just say the word if you're curious which health insurer deserves a core spot in your portfolio 💹📌

Edit in a page